Evidence map›Paper›PMID 37762197›Full record

ArticleInternational journal of molecular sciences2023

Complement System Inhibitory Drugs in a Zebrafish (

Dayanne Carla Fernandes, Denise V Tambourgi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dayanne Carla FernandesImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0003-2037-1397
Denise V TambourgiImmunochemistry Laboratory, Butantan Institute, São Paulo 05503-900, Brazil.ORCID 0000-0003-1896-9074
Instituto Butantan · BR

Funding

São Paulo Research Foundation 2013/07467-1
6 · The paper itself

Abstract

The dysregulation of complement system activation usually results in acute or chronic inflammation and can contribute to the development of various diseases. Although the activation of complement pathways is essential for innate defense, exacerbated activity of this system may be harmful to the host. Thus, drugs with the potential to inhibit the activation of the complement system may be important tools in therapy for diseases associated with complement system activation. The synthetic peptides Cp40 and PMX205 can be highlighted in this regard, given that they selectively inhibit the C3 and block the C5a receptor (C5aR1), respectively. The zebrafish (

Indexed as

Complement ActivationZebrafishAnimalsComplement Inactivating AgentsComputer SimulationMolecular Docking SimulationComplement Inactivating AgentsC3aC5aC5aR1Cp40PMX205

Identifiers

PMID37762197
PMCPMC10530807
OpenAlexW4386602285

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.